Ibrutinib and ABT199 for CLL

Jennifer Brown, MD, PhD

Video Categories: ASH 2014

Jennifer R. Brown, MD, PhD, at Dana-Farber Cancer Institute in Boston, discusses what she believes are the most important items coming out of ASH for CLL this year. She mentions excellent study results being presented about the drugs ibrutinib and ABT199.
November 24, 2014

Personalizing Cancer Treatment Based on Unique Genetic Profile

Gary Palmer, MD, explains how research is ahead of the physician and patient and the need to educate the physician and patient on all the information about DNA and what drives the cancer.

October 16, 2015

Targeting Multiple Pathways with Immunotherapies

Dr. Sanjiv Agarwala brings up the potential issue of toxicity that may arise in combining immunotherapies and argues that the benefits outweigh the risks.